Hematology medical calculators
All 16 Hematology medical calculators on DocMath, A–Z. All specialties
- 4Ts score (heparin-induced thrombocytopenia)Pretest probability of HIT in a patient with thrombocytopenia on heparin; guides testing and switching to a non-heparin anticoagulant.
- Absolute neutrophil count (ANC)ANC from the white cell count and a manual differential; grades neutropenia (ASCO/IDSA definitions).
- COMPASS-CAT score (VTE risk in outpatients on cancer treatment)Risk of symptomatic VTE in ambulatory patients with breast, colorectal, lung or ovarian cancer who are receiving anticancer treatment (simplified score, 0–28; high risk ≥7).
- French TMA score (severe acquired ADAMTS13 deficiency)Pre-test likelihood of severe acquired ADAMTS13 deficiency (immune TTP) in adults with idiopathic thrombotic microangiopathy, from platelet count, creatinine and antinuclear antibodies.
- HERDOO2 rule (stopping anticoagulation after unprovoked VTE in women)Identifies women with a first unprovoked major VTE who are at low risk of recurrence and may stop anticoagulants after the initial treatment period. Not applicable to men.
- HScore (reactive haemophagocytic lymphohistiocytosis)Probability of reactive (secondary) haemophagocytic syndrome / HLH in adults from 9 clinical, laboratory and marrow variables.
- IMPROVE bleeding risk score (medical inpatients)In-hospital bleeding risk at admission in acutely ill medical patients; a score ≥7 marks high bleeding risk when considering pharmacological thromboprophylaxis.
- IPSS-R (Revised International Prognostic Scoring System, MDS)Prognostic risk category (survival and AML evolution) for untreated primary myelodysplastic syndromes from karyotype, marrow blasts and cytopenias; optional age adjustment (IPSS-RA).
- ISTH overt DIC score (2025 update)Diagnoses overt (late-phase) disseminated intravascular coagulation in a patient with an underlying condition known to cause DIC.
- Khorana score (chemotherapy-associated VTE)Risk of symptomatic VTE in ambulatory patients with cancer starting chemotherapy; selects patients for thromboprophylaxis.
- NCCN-IPI (diffuse large B-cell lymphoma)Enhanced International Prognostic Index for de novo DLBCL treated with rituximab-based chemotherapy: 0–8 points, four risk groups.
- Ottawa score (recurrent cancer-associated VTE)Risk of recurrent VTE during the first 6 months of anticoagulation in patients with cancer-associated VTE.
- Padua Prediction Score (VTE risk in medical inpatients)Identifies hospitalized medical patients at high risk of venous thromboembolism (score ≥4) to guide thromboprophylaxis decisions.
- PLASMIC score (severe ADAMTS13 deficiency / TTP)Seven-item score (0–7) estimating the likelihood of severe ADAMTS13 deficiency (TTP) in adults with thrombotic microangiopathy, while ADAMTS13 results are pending.
- R-ISS (Revised International Staging System, multiple myeloma)Stages newly diagnosed multiple myeloma from ISS (β2-microglobulin, albumin), high-risk FISH abnormalities and LDH.
- R2-ISS (second revision of the ISS, multiple myeloma)Additive score (0–5) that splits newly diagnosed multiple myeloma into four overall-survival groups, adding 1q gain/amplification to ISS, del(17p), t(4;14) and LDH.